SCD Cardiovascular, Pulmonary, and Renal Scope
| Element Considered | Final Measures in Toolkit |
|---|---|
| N-terminal-pro-brain natriuretic peptide (NT-proBNP) | N-terminal-pro-brain natriuretic peptide (NT-proBNP) |
| Cardiovascular Complications | |
| Right Heart Catheterization (RHC) | Right Heart Catheterization (RHC) |
| Iron overload | Serum or Plasma Ferritin |
| Hemolytic Component | Reticulocyte Count |
| Haptoglobin Level | |
| Bilirubin Level | |
| Lactate Dehydrogenase Level | |
| Red Blood Cell Aspartate Aminotransferase Level | |
| Brachial Artery Relaxivity | |
| Short Axis Function | |
| Pulmonary Complications | |
| Asthma/airways disease | Lung Function - Diffusion Capacity |
| Lung Function - Lung Volume | |
| Acute chest syndrome | Chest X-ray |
| Sleep Disordered Breathing | |
| Other Complications | |
| Temperature | Body Temperature |
| Liver iron |
SCD Neurology, Quality of Life, and Health Services Scope
| Element Considered | Final Measures in Toolkit |
|---|---|
| Neurologic Complications | |
| Silent Stroke | Stroke Impact/Outcome |
| Overt Stroke | Functionality after Stroke |
| Transcranial Doppler (TCD) | Stroke Risk in Children with Sickle Cell Disease |
| Diffusion Tensor Imaging (DTI) | |
| Angiography | |
| Non-stroke neurologic complications | |
Cognitive complications
|
Adaptive Behavior/Adaptive Function |
| Intelligence Scale | |
| Transfusion | |
| Acute and Chronic Pain | |
| Interference | |
Use of Substances of Addiction
|
|
| Transfusion | |
| Quality of Life and Patient-Reported Outcomes | |
Functional measures of well-being
|
Quality of Life in Sickle Cell Disease |
| Self-efficacy in Sickle Cell Disease | |
Pain
|
|
Activities of Daily Living
|
|
| Health Services | |
| Quality of Care - Hospitalization, re-hospitalization - TCD, treatments, medications | Quality of Care |
| Preventive care (flu shots, hydroxyurea) | |
| Acute Care | |
| Quality indicators for pediatric sickle cell disease |
SCD Curative Therapies Scope
| Element Considered | Final Measures in Toolkit |
|---|---|
| Indications for Transplant | |
| Pretransplant Evalution | Prothrombin Time |
| Left Ventricular Global Longitudinal Strain by Speckle Tracking Echocardiography | |
| Determination of Liver Iron Concentration by R2* | |
| Determination of Liver Iron Concentration by Ferriscan | |
| Determination of Liver Fibrosis by Magnetic Resonance Elastography (MRE) (Supplemental Information) | |
| Recurrent Priapism | |
| Psychosocial Assessment of Candidates for Transplantation | |
| Fibrosis Staging of Liver Biopsy (Supplemental Information) | |
| Determination of Liver Fibrosis by Transient Elastography (Supplemental Information) | |
| Myocardia Iron Estimation Using T2* MRI (Supplemental Information) | |
| Description of transplant conditioning regimen | Sickle Cell Disease Transplant Conditioning Regimen |
| Transplant stem cell source | Sickle Cell Disease Stem Cell Source and Cell Manipulation |
| Effect of transplant on donor derived erythropoiesis | |
| Endpoints for curative therapy (complications) | White Cell Chimerism and Graft Failure |
| Graft versus Host Disease | |
| Pretransfusion evaluation | |
| Endpoints for Transfusion | Pre-transfusion Antibody Testing |
| Transfusion Reaction Reporting | |
| Thyroid Stimulating Hormone (hTSH) in Serum | |
| Endpoints for transplant (complications) | Determination of Liver Iron Concentration by R2* |
| Determination of Liver Iron Concentration by Ferriscan | |
| Determination of Liver Fibrosis by Magnetic Resonance Elastography (MRE) (Supplemental Information) | |
| Fibrosis Staging of Liver Biopsy (Supplemental Information) | |
| Determination of Liver Fibrosis by Transient Elastography (Supplemental Information) | |
| Myocardia Iron Estimation Using T2* MRI (Supplemental Information) |
SCD Pain Scope
| Element Considered | Final Measures in Toolkit |
|---|---|
| Intensity | Pain Intensity |
| Location | Pain Location |
| Pain Quality | Pain Quality Descriptors |
| Anxiety: Pain-related, state, trait, disorder | |
| Catastrophizing | Pain Catastrophizing |
| Coping | Pain Coping |
| Emotional | |
| Psychosocial | |
| Self-efficacy | |
| Social | |
| Care utilization | |
| Frequency | |
| Pain Burden | Pain Burden |
| Physical Interference/Impact | Pain Interference |
| Physical Mobility | |
| Medication use | Treatment Response: Medication Use |
| Patient reported treatment, satisfaction, or effectiveness | Patient Reported Impression of Change |
SCD Psychosocial and Social Determinants of Health Scope
| Element Considered | Final Measures in Toolkit |
|---|---|
| Transition Readiness | Sickle Cell Disease Transition Readiness Assessment |
| Sickle Cell Disease Transition Readiness Assessment (SI) | |
| Response to Stress | Sickle Cell Disease Responses to Stress - Youth |
| Sickle Cell Disease Responses to Stress - Parent Report | |
| Self-Management | Sickle Cell Disease Self-Management - Adolescent Skills Checklist |
| Sickle Cell Disease Self-Management - Caregiver Skills Checklist | |
| Stigma | Sickle Cell Disease Health-Related Stigma - Child |
| Sickle Cell Disease Health-Related External Stigma - Adolescent and Adult | |
| Sickle Cell Disease Health-Related Internal Stigma - Adolescent and Adult | |
| Trust in Medical Care and Research | Trust in the Medical Professional - Adult |
| Trust in Medical Researchers - 12-item | |
| Trust in Medical Researchers - 4-item | |
| Grief | Inventory of Complicated Grief |
| Reactions to Loss Scale | |
| Resilience | Resilience |
| Spiritual Coping | Religious Behaviors and Congregational Support |
| Attitude Toward Illness | Attitude Toward Illness - Child (SI) |
| Self-Efficacy | General Self-Efficacy - Child (SI) |
| General Self-Efficacy - Adolescent (SI) | |
| General Self-Efficacy - Child Parent Report (SI) | |
| General Self-Efficacy - Adult (SI) | |
| Illness Identity | Illness Identity Questionnaire (SI) |
| Medication Adherence | Medication Adherence (SI) |
| Optimism | Optimism (SI) |
| Self-Perception | Self-Perception Profile - Child (SI) |
| Self-Perception Profile - Adolescent (SI) | |
| Self-Perception Profile - Adult (SI) |
SCD Genitourinary Scope
| Element Considered | Final Measures in Toolkit |
|---|---|
| Puberty | |
| Menstruation | Sickle Cell Disease Pain Associated with Menstruation |
| Sickle Cell Disease Pain Associated with Menstruation - Quality of Life | |
| Contraception | Female Contraception Use |
| Priapism | Priapism |
| Fertility | Fertility and Quality of Life |
| Fertility History | |
| Infertility | |
| Testosterone Deficiency | Testosterone Level |
| Sexual Function | Sexual Function |
| Sexual, Romantic, and Partner Satisfaction | |
| Exogenous hormone use | Hormone Therapy |
| Menopause | Perimenopausal Symptoms |
| Voiding Dysfunction | Overactive Bladder |
SCD Pregnancy Scope
| Element Considered | Final Measures in Toolkit |
|---|---|
| Pre-Implantation Genetic Diagnosis | |
| Non-Invasive Prenatal Testing | Cell-free Fetal DNA Testing for Sickle Cell Disease (Supplemental Information) |
| Chorionic Villus Sampling (CVS) | Invasive Prenatal Testing Guidelines (Supplemental Information) |
| Amniocentesis | Invasive Prenatal Testing Guidelines (Supplemental Information) |
| Acute Chest Syndrome | Acute Chest Syndrome During Pregnancy |
| Acute Chest Syndrome - General Populations (Supplemental Information) | |
| Transfusion | Prophylactic Transfusion during Pregnancy |
| Transfusion Indications | |
| Transfusion Reactions | |
| Hydroxyurea | Hydroxyurea Use during Pregnancy |
| Hydroxyurea Use Adherence - Prospective Studies | |
| Thromboprophylaxis | Thromboprophylaxis |
| Thrombosis - Catheter-related | |
| Thrombosis - Venous | |
| Multidisciplinary Care for SCD | Multidisciplinary Care for Sickle Cell Disease Pregnancies (Supplemental Information) |